FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2051266276> ?p ?o ?g. }

• W2051266276 endingPage "585" @default.
• W2051266276 startingPage "584" @default.
• W2051266276 abstract "Thrombotic Thrombocytopenic Purpura (TTP) and Antiphospholipid Syndrome (APS) are two well-differentiated processes. TTP is an infrequent disease characterized by microangiopathic haemolytic anaemia, thrombocytopenia, neurological manifestations and renal failure. The occlusion of the microvessels by microthrombi, mainly composed of platelets, constitutes the basic lesion of this condition. It is apparently a consequence of the unusually large von Willebrand factor multimers, due to congenital ADAMTS13 deficiency or the presence of anti ADAMTS13 (Moake et al, 1982). In contrast, APS constitutes a frequently diagnosed syndrome, characterized by recurrent thrombosis, obstetrical morbidity and the presence of antiphospholipid (aPL) antibodies. An unusual clinical APS presentation, called Catastrophic APS, consists of multi-organ failure secondary to a thrombosis, involving both large vessels and microcirculation, thrombocytopenia and microangiopathic anaemia and could make a differential diagnosis with TTP difficult (Asherson et al, 2003). Antiphospholipid syndrome can be primary or associated with other autoimmune diseases, but a clinical association of APS and TTP has been rarely described. In most patients, the diagnosis was established only on the basis of clinical criteria (Espinosa et al, 2004). Paradoxically, a high prevalence of anti ADAMTS13 antibodies and/or ADAMTS13 dysfunction in patients with APS or aPL antibodies has been reported (Austin et al, 2008), although without clinical significance. Despite these findings, we describe here a case of apparent APS and TTP association. A 49-year-old woman with a Lupus Anticoagulant (LA), but without a prior clinical history of thrombosis or miscarriage despite having had five children and several surgical procedures, developed recurrent arterial brain thrombosis, followed in a very short period of time by severe TTP with very low levels of ADAMTS 13 and high levels of anti ADAMTS 13 antibodies. Initially, the patient was referred to the Haematology Department in June 2006 for mild anaemia: haemoglobin 114 g/l, thrombocytopenia 63 × 109/l and a prolonged activated partial thromboplastin time (APTT). Iron, vitamin B12 and Folic acid levels were normal, and there were no haemolytic data. The APTT was 52 s (normal control: 30 s), which was not corrected when mixed with normal plasma. Because of her good general state, she was scheduled for a further study of probable LA. However, 2 months later (August 2006) the patient presented at the emergency room with a sudden episode of right side hemiparesis. The computed tomography scan was normal, and with a diagnosis of suspected atherothrombotic brain stroke, the patient was hospitalized and started on a treatment of aspirin, 300 mg/d. At that time the laboratory tests showed haemoglobin 109 g/l, platelet count 43 × 109/l and APTT 52 s. In the following days, the platelet count decreased to 17 × 109/l, but without changes in the other haematological parameters. Uric acid was 0·45 μmol/l, total bilirubin 23·9 μmol/l; lactic dehydrogenase (LDH) levels were normal. The investigation of LA using APTT LA time and the diluted Russell Viper Venom Test (Instrumentation Laboratory, Lexington, MA, USA) was positive: APTT-LA: 86·7 s APTT-LA ratio: 2·41, dilute viper venom (DVV) test: 56·8 s, DVV test ratio: 1·43 (positive >1·21). Anti-Beta2 Glycoprotein1 IgG and IgM antibodies (Aesku Diagnostics, Waldesheim, Germany) were 18·3 and 1·3 U/ml, respectively. Antinuclear antibodies (titre, 1:640), anti-ribonucleoprotein and antihistone antibodies were positive, but Systemic Lupus was discarded because of the absence of other criteria. Initially diagnosed as an Immune Thrombocytopenic Purpura associated with APS, the patient was treated with corticosteroids and a high dose of immunoglobulins without response. Fourteen days after her latest presentation, the patients neurological condition worsened. A cranial magnetic resonance imaging scan showed a sub-acute ischemic infarction in the left parietal region. Laboratory tests were haemoglobin of 82 g/l, platelet count 11 × 109/l and an increased LDH of 737 iu per ml. Two days later schistocytes were observed in blood smears. Her platelet count had fallen to 4 × 109/l and the serum haptoglobin was undetectable. ADAMTS13 levels were 48·2 μg/l (normal >208·7 μg/l) and anti ADAMTS13 antibodies 46·9 AU/ml (normal <12·74 AU/mL) (Inmubind®; American Diagnostica, Greenwich, CT, USA). With the definitive diagnosis of TTP associated with an APS, the patient was started on a combined treatment of daily plasmatic exchange with fresh frozen plasma, plasma transfusion every 6 h and a weekly dose of Rituximab (375 mg/m2). The patient received a total of 18 plasmaphereses and four Rituximab doses. A progressive response occurred, with a complete neurological and haematological recovery. As soon it was possible, an oral anticoagulation with acenocoumarol was started. Two years later, the patient remained asymptomatic, with platelet counts over 150 × 109/l, normal ADAMTS13 levels and absence of anti ADAMTS13 antibodies. The patient is currently under permanent anticoagulation with dicumarin. A clear association between APL and TTP has rarely been reported. In one study (Amoura et al, 2004), two patients with a simultaneous clinical picture of TTP and APS with LA, anticardiolipin, anti ADAMTS13 antibodies and ADAMTS13 low levels, were described. This association is controversial, and recent articles have recommended against the diagnosis of TTP in the presence of aPL antibodies (Porta et al, 2005). Other reports, when aPL antibodies and microangiopathic thrombosis has been observed, have suggested that aPL antibodies could be a consequence of the endothelial damage, but not a cause of the disease. (Asherson et al, 2008). There are isolated findings that could explain a sporadic relationship between APS and TTP. One such finding points out that, although ADAMTS13 deficiency and anti ADAMTS13 antibodies basically cause microcirculation thrombosis, there is a possibility that occasionally large vessel thrombosis in organs, such as the brain, could be a primary manifestation (Downes et al, 2004). In its turn, there is some evidence that the aPL activity creates an increased tissue factor production in extensive vascular regions (catastrophic APS) (Urbanus et al, 2008). It seems probable that systematic testing of ADAMTS13 and anti-ADAMTS13 antibodies in APS patients with neurological symptoms could identify cases of the underdiagnosed TTP-APS combination. Nevertheless, according to the findings of Austin et al (2008), the widespread prevalence of ADAMTS13 low activity and a variety of heterogeneous anti-ADAMTS13 antibodies in aPL positive patients without thrombotic events creates further questions." @default.
• W2051266276 created "2016-06-24" @default.
• W2051266276 creator A5009655334 @default.
• W2051266276 creator A5009857013 @default.
• W2051266276 creator A5023103651 @default.
• W2051266276 creator A5026918206 @default.
• W2051266276 creator A5031584869 @default.
• W2051266276 creator A5063250153 @default.
• W2051266276 creator A5071417288 @default.
• W2051266276 creator A5082017518 @default.
• W2051266276 date "2009-10-27" @default.
• W2051266276 modified "2023-10-17" @default.
• W2051266276 title "Concurrent thrombotic thrombocytopenic purpura and antiphospholipid syndrome: a rare and severe clinical combination" @default.
• W2051266276 cites W1997083411 @default.
• W2051266276 cites W2007147462 @default.
• W2051266276 cites W2026994059 @default.
• W2051266276 cites W2041065426 @default.
• W2051266276 cites W2091241280 @default.
• W2051266276 cites W2105482507 @default.
• W2051266276 cites W2110832637 @default.
• W2051266276 cites W2122557297 @default.
• W2051266276 cites W2146264215 @default.
• W2051266276 doi "https://doi.org/10.1111/j.1365-2141.2009.07856.x" @default.
• W2051266276 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19694716" @default.
• W2051266276 hasPublicationYear "2009" @default.
• W2051266276 type Work @default.
• W2051266276 sameAs 2051266276 @default.
• W2051266276 citedByCount "7" @default.
• W2051266276 countsByYear W20512662762013 @default.
• W2051266276 countsByYear W20512662762016 @default.
• W2051266276 countsByYear W20512662762017 @default.
• W2051266276 countsByYear W20512662762020 @default.
• W2051266276 crossrefType "journal-article" @default.
• W2051266276 hasAuthorship W2051266276A5009655334 @default.
• W2051266276 hasAuthorship W2051266276A5009857013 @default.
• W2051266276 hasAuthorship W2051266276A5023103651 @default.
• W2051266276 hasAuthorship W2051266276A5026918206 @default.
• W2051266276 hasAuthorship W2051266276A5031584869 @default.
• W2051266276 hasAuthorship W2051266276A5063250153 @default.
• W2051266276 hasAuthorship W2051266276A5071417288 @default.
• W2051266276 hasAuthorship W2051266276A5082017518 @default.
• W2051266276 hasBestOaLocation W20512662761 @default.
• W2051266276 hasConcept C126322002 @default.
• W2051266276 hasConcept C187212893 @default.
• W2051266276 hasConcept C203014093 @default.
• W2051266276 hasConcept C2776874634 @default.
• W2051266276 hasConcept C2778585876 @default.
• W2051266276 hasConcept C2780868729 @default.
• W2051266276 hasConcept C71924100 @default.
• W2051266276 hasConcept C89560881 @default.
• W2051266276 hasConceptScore W2051266276C126322002 @default.
• W2051266276 hasConceptScore W2051266276C187212893 @default.
• W2051266276 hasConceptScore W2051266276C203014093 @default.
• W2051266276 hasConceptScore W2051266276C2776874634 @default.
• W2051266276 hasConceptScore W2051266276C2778585876 @default.
• W2051266276 hasConceptScore W2051266276C2780868729 @default.
• W2051266276 hasConceptScore W2051266276C71924100 @default.
• W2051266276 hasConceptScore W2051266276C89560881 @default.
• W2051266276 hasIssue "4" @default.
• W2051266276 hasLocation W20512662761 @default.
• W2051266276 hasLocation W20512662762 @default.
• W2051266276 hasOpenAccess W2051266276 @default.
• W2051266276 hasPrimaryLocation W20512662761 @default.
• W2051266276 hasRelatedWork W1969414007 @default.
• W2051266276 hasRelatedWork W1971316336 @default.
• W2051266276 hasRelatedWork W2003130009 @default.
• W2051266276 hasRelatedWork W2005335438 @default.
• W2051266276 hasRelatedWork W2026994059 @default.
• W2051266276 hasRelatedWork W2047645365 @default.
• W2051266276 hasRelatedWork W2111739542 @default.
• W2051266276 hasRelatedWork W2527696784 @default.
• W2051266276 hasRelatedWork W3032157229 @default.
• W2051266276 hasRelatedWork W4249042456 @default.
• W2051266276 hasVolume "147" @default.
• W2051266276 isParatext "false" @default.
• W2051266276 isRetracted "false" @default.
• W2051266276 magId "2051266276" @default.
• W2051266276 workType "article" @default.